AbCellera-discovered antibody bebtelovimab receives FDA EUA for COVID-19 treatment

AbCellera Biologics Inc.

Bebtelovimab (LY-CoV1404) authorized for mild-to-moderate COVID-19 in high-risk patients 12+.
Neutralizes Omicron including BA.2 and all known variants; binds rarely mutated spike region.
Second AbCellera antibody from Lilly collaboration; dosage 175 mg IV injection.
U.S. government agreed to buy up to 600,000 doses by March 2022, option for 500,000 more.
CEO Hansen highlights potency; previous antibody bamlanivimab also received EUA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.